All In Biotech

Drug Trial Radar · NCT07070349

A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors

A Phase I/II Clinical Study to Evaluate the Safety, Radiation Dosimetry, Pharmacokinetics, and Preliminary Diagnostic Efficacy of HRS-6213 in Healthy Subjects and Patients With Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jul 10, 2025

Primary completion

Jan 2026

Study completion Mar 2026

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, radiation dosimetry, pharmacokinetics, and preliminary diagnostic efficacy of HRS-6213.

Conditions

  • Patients With Solid Tumors

Interventions

  • HRS-6213Drug

    HRS-6213 IV administered as imaging agent for PET scan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence of adverse events (AEs) of HRS-6213Time frame: From first dose of study drug to end of treatment (up to approximately 7 days)
  2. Phase 1: Radiation dosimetryTime frame: From first dose of study drug to end of treatment (up to approximately 7 days)
  3. Phase 2: With reference to the Standard of Truth (SOT), evaluate the diagnostic efficacy indicators of HRS-6213 PET at the lesion levelTime frame: rom first dose of study drug to end of treatment (up to approximately 60 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.